These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34856868)

  • 41. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19 vaccine: where are we now and where should we go?
    Soleimanpour S; Yaghoubi A
    Expert Rev Vaccines; 2021 Jan; 20(1):23-44. PubMed ID: 33435774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of COVID-19 vaccines.
    Graña C; Ghosn L; Evrenoglou T; Jarde A; Minozzi S; Bergman H; Buckley BS; Probyn K; Villanueva G; Henschke N; Bonnet H; Assi R; Menon S; Marti M; Devane D; Mallon P; Lelievre JD; Askie LM; Kredo T; Ferrand G; Davidson M; Riveros C; Tovey D; Meerpohl JJ; Grasselli G; Rada G; Hróbjartsson A; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD015477. PubMed ID: 36473651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE-An Observational Study.
    Ganesan S; Al Ketbi LMB; Al Kaabi N; Al Mansoori M; Al Maskari NN; Al Shamsi MS; Alderei AS; El Eissaee HN; Al Ketbi RM; Al Shamsi NS; Saleh KM; Al Blooshi AF; Cantarutti FM; Warren K; Ahamed F; Zaher W
    Front Public Health; 2022; 10():876336. PubMed ID: 35602146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
    Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
    BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.
    Patel R; Kaki M; Potluri VS; Kahar P; Khanna D
    Hum Vaccin Immunother; 2022 Dec; 18(1):2002083. PubMed ID: 35130825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.
    Upreti S; Samant M
    Pharm Res; 2022 Sep; 39(9):2119-2134. PubMed ID: 35773445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population.
    Genç Bahçe Y; Acer Ö; Özüdoğru O
    Curr Microbiol; 2023 May; 80(6):206. PubMed ID: 37160453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
    Feikin DR; Higdon MM; Abu-Raddad LJ; Andrews N; Araos R; Goldberg Y; Groome MJ; Huppert A; O'Brien KL; Smith PG; Wilder-Smith A; Zeger S; Deloria Knoll M; Patel MK
    Lancet; 2022 Mar; 399(10328):924-944. PubMed ID: 35202601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
    Li Q; Wang J; Tang Y; Lu H
    Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.
    Kyaw MH; Spinardi J; Zhang L; Oh HML; Srivastava A
    Hum Vaccin Immunother; 2023 Dec; 19(1):2165856. PubMed ID: 36727201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.